MINI-REVIEW

Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients

Abhishek Shankar¹*, Shubham Roy², Abhidha Malik¹, PK Julka¹, GK Rath¹

Abstract

The supportive care of patients receiving antineoplastic treatment has dramatically improved over the past few years and development of effective measures to prevent nausea and vomiting after chemotherapy serves as one of the most important examples of this progress. A patient who starts cancer treatment with chemotherapy lists chemotherapy-induced nausea and vomiting as among their greatest fears. Inadequately controlled emesis impairs functional activity and quality of life, increases the use of health care resources, and may occasionally compromise adherence to treatment. New insights into the pathophysiology of chemotherapy-induced nausea and vomiting, a better understanding of the risk factors for these effects, and the availability of new antiemetic agents have all contributed to substantial improvements in emetic control. This review focuses on current understanding of chemotherapy-induced nausea and vomiting and the status of pharmacological interventions for their prevention and treatment.

Keywords: Prevention - chemotherapy - nausea and vomiting - cancer patients

Introduction

Malignant neoplasms remain a leading cause of death worldwide (Siegel et al., 2014). At the beginning of this century, comprehensive treatment for malignant neoplasm had progressed considerably with advances in molecular targeted therapy, immunotherapy and gene therapy. However, chemotherapy is still the primary treatment. Chemotherapy-induced nausea and vomiting (CINV) is the most common and intolerable adverse event, which impedes or even interrupts the scheduled therapeutic program and severely impairs the efficacy (Hassan and Yusoff, 2010; Janelsins et al., 2013; Keat et al., 2013; nccn, 2014). The goal of each antiemetic therapy is to prevent chemotherapy-induced nausea and vomiting (CINV). Twenty years ago, these were inevitable adverse events of chemotherapy and forced up to 20% of patients to postpone or refuse potentially curative treatment (Jordan et al., 2007).

Clinical and basic research over the past 25 years has led to steady improvements in the control of CINV. The chemotherapy available in the 1950s and 1960s varied greatly in its capacity to induce emesis. Agents such as vinca alkaloids and 5-fluorouracil were in common usage, and only infrequently caused emesis. In contrast, nitrogen mustard were known for association with emesis. There was some awareness of the problem of CINV, but appreciation of its magnitude was not great (Gralla, 1993).

Based on the current studies, it is generally believed that 5-HT3 plays a dominant role in acute vomiting, while substance P seems to play a more important role in delayed vomiting (Bergstrom et al., 2011).

In cisplatin-induced CINV, serum 5-HT3 levels peak at 6-8 h after the administration of cisplatin. At this time-point, the clinical symptoms are obvious and the efficacy of 5-HT3 antagonists is excellent. Neurokinin-1 (NK1) receptor antagonists are effective for both acute and delayed vomiting, especially the latter, on which the studies are also focused. The advent and application of Palonosetron, a second-generation 5-HT3 antagonist, furthers our understanding of the mechanisms of CINV. In contrast to the first-generation 5-HT3 antagonist, it is efficacious in both acute and delayed CINV. If this efficacy is based solely on enhanced binding to the receptors and lengthened half-life, then increased administration frequency or dosage of the first-generation drugs should ensure binding saturation of receptors; however, this is not the case.

More extensive studies have indicated that the 5-HT3 receptor that binds Palonosetron has allosteric sites, and that internalization occurs following binding, thus inhibiting receptor recycling for up to 2.5h (Rojas et al., 2010; Rojas et al., 2014). Additionally, Palonosetron treats both acute and delayed vomiting via the crosstalk that exists between the 5-HT3 and substance P receptor pathways (Rojas et al., 2014).

Corticosteroids show good antiemetic efficacy in the prevention of acute and delayed emesis, especially...
when combined with other antiemetic agents. However, their role is sometimes underestimated. Another group of antiemetic, the neurokinin-1 (NK-1) receptor antagonists, has been developed. The first drug in this class, Aprepitant, was approved in 2003 (Hesketh et al, 2003).

Another drug Fosaprepitant in intravenous form was approved for prevention of chemotherapy induced acute and delayed emesis.

Studies have shown that the patients benefit from the use of Aprepitant in combination with standard antiemetic therapy, both in the acute and delayed setting of highly and moderately emetogenic chemotherapy. However, although significant progress has been made with the development of a number of effective and well tolerated antiemetic treatments, CINV remains an important adverse effect of treatment.

**History of development of chemotherapy and antiemetic therapy for CINV**

- **1950-60** Nitrogen mustard and Actinomycin D induce severe emesis
- **1960** Introduction of phenothiazines - antiemetic effect via D2 blockage, Area postrema responsible for emesis by chemotherapy (Barison)
- **1970s** Introduction of cisplatin, no effective antiemetic therapy available; Metaclopromide found to have antiemetic efficacy
- **1980s** High dose metaclopromide improves antiemetic response rates; Introduction of steroids in prophylaxis; Studies with Ondansetron
- **1990s** Introduction of 5-HT3 RA - Milestones in antiemetic therapy
- **2003** Introduction of palanosetron - Second generation 5-HT3-RA
- **2003** Approval for first NK-1 RA - Aprepitant
- **2008** FDA approval of IV NK-1 RA - Fosaprepitant
- **2011** EMA approval of IV NK-1 RA - Fosaprepitant

**Pathophysiology of CINV**

The central nervous system plays a critical role in the physiology of nausea and vomiting, serving as the primary site that receives and processes a variety of emetic stimuli. The central nervous system also plays a primary role in generating efferent signals which are sent to a number of organs and tissues in a process that eventually results in vomiting. It was Wang and Borison who first proposed the idea of a vomiting centre (Wang and Borison, 1950).

**Mechanism of CINV**

Three key components involving area in the hindbrain and the abdominal vagal afferents have been identified. Now a day, it is thought that the existence of anatomically discrete vomiting centres is unlikely (Hesketh, 2008). The locations of neurons that coordinate the bodily functions associated with emesis are spread throughout the medulla, supporting the notion that a central pattern generator receives indirect input from both the area postrema (chemoreceptor trigger zone) and the abdominal vagus by means of the nucleus tractus solitaries.

**Chemoreceptor Trigger Zone (CTZ):** The Chemoreceptor Trigger Zone is located in the area postrema at the bottom end of the fourth ventricle. The area postrema has afferent and efferent connections with underlying structures, the subnucleus gelatinosus and nucleus tractus solitaries, receiving vagal afferent fibres from the gastrointestinal tract.

**Abdominal vagal afferents:** The abdominal vagal afferents appear to have the greatest relevance for CINV. A variety of receptors, including 5-HT, NK-1, and cholecystokinin-1, are located on the terminal ends of the vagus afferents. The receptors lie in close proximity to the enterochromaffin cells located in the gastrointestinal mucosa of the proximal small intestine, which contains a number of local mediators, such as 5-HT, substance P and cholecystokinin.

**Neurotransmitters:** Research over the past three decades have gradually elucidated the clinical significance of several neurotransmitters in the vomiting process. The neurotransmitters serotonin, substance P and dopamine all appear to play important roles in this process.

**Classification of Nausea and Vomiting**

**CINV can be classified into three categories**

- **Acute Onset Nausea and Vomiting:** Occurring within 24 hours of initial administration of chemotherapy. Mainly by serotonin (5-HT) release from the enterochromaffin cells
- **Delayed Onset Nausea and Vomiting:** After 24 hours to 5 days after chemotherapy. Various mechanism - Mainly substance P mediated, disruption of the blood-brain barrier, disruption of the gastrointestinal motility, adrenal hormones (Roila et al., 2002)
- **Anticipatory Nausea and Vomiting:** Occurrence is possible after 1 cycle of chemotherapy. Involves an element of classic conditioning. Triggered by taste, odour, sight, thoughts or anxiety secondary to a history of poor response to antiemetic agents (Roila et al., 2002; Aapro et al., 2005).

**Associated Risk Factors**

**Emetogenic potential of chemotherapy**

It is thought that chemotherapy is the most important risk factor.
risk factors for the occurrence of CINV. The emetogenic potential of chemotherapeutic agents is classified into four emetic risk groups: high, moderate, low and minimal (Hesketh et al., 1997; Grunberg et al., 2005; Kris et al., 2006).

The emetogenic potential of an antineoplastic therapy varies with specific drug used ranging from cisplatin, which results in severe vomiting in almost all patients, to vinca alkaloids, with only minimal inducible emesis. The chemotherapeutic agents can cause different intention of emesis, depending on the way the drugs are administered.

### Patient risk factors

Following is a breakdown of factors that increase susceptibility to nausea and vomiting.

- **Previous experience of poorly controlled emesis**: If patients have previous experience of poorly controlled emesis they are more likely to develop post-chemotherapy nausea and vomiting in response to a new treatment. If emesis control was sufficient during previous chemotherapy, the percentage of patients who do not experience emesis in subsequent chemotherapy courses is larger than it is for patients who had insufficient previous

### Table 1. Chart of Emetogenic Risk of Intravenous Chemotherapeutic Agents and Oral Chemotherapeutic Agents

| Level 1 (minimal risk, <10%) | Level 2 (low risk, 10-30%) | Level 3 (moderate risk, 31-90%) | Level 4 (high risk, >90%) |
|-----------------------------|---------------------------|-------------------------------|-------------------------|
| Intravenous                 |                           |                               |                         |
| Bevacizumab                 | Asparaginase              | Alemtuzumab                   | Actinomycin D           |
| Bleomycin                   | Bortezomib                | Altretamine                   | Carmustine              |
| Busulfan                    | Catumaxomab              | Azacitidine                   | Cisplatin               |
| Chlorambucil                | Cetuximab                 | Bendamustine                  | Cyclophosphamide (>1.5 g/ m²) |
| Cladribine                  | Cytarabine (<1 gm/m²)    | Clofarabine                   | Dacarbazine             |
| Cytarabine (<100 mg/m²)     | Docetaxel                 | Carboplatin                   | Lomustine               |
| Fludarabin                  | Doxorubicin liposomal    | Cyclophosphamide (≥1.5 g/ m²) | Mechlorethamine         |
| Hormones                    | Etoposide                 | Cytarabine (>1 g/m²)         | Pentostatin             |
| Hydroxyurea                 | 5-Fluorouracil           | Daunorubicin                  | Streptozocin            |
| Interferon                  | Gemcitabine               | Doxorubicin                   |                         |
| Mercaptopurine              | Ixabepilone              | Carbothron                   |                         |
| Methotrexate (<100 mg/m²)   | Methotrexate (>100 mg/m²) | Carbothron                   |                         |
| Thioguanine                 | Mitoxantrone(<12 mg/m²)  | Iosfamide                     |                         |
| Vinblastine                 | Paclitaxel               | Irinotecan                    |                         |
| Vinristine                  | Paclitaxel               | Irinotecan                    |                         |
| Vinorelbine                 | Pegasparginase           | Mitoxantrone(>12 mg/m²)      |                         |
| *Percentages indicate the risk of vomiting with intravenously administered antineoplastic agents in the absence of antiemetic prophylaxis; Data from Jordan et al. (2007), Kris et al.(2006), Roila et al. (2006,2010).* |

### Oral

| Level 1 (minimal risk, <10%) | Level 2 (low risk, 10-30%) | Level 3 (moderate risk, 31-90%) | Level 4 (high risk, >90%) |
|-----------------------------|---------------------------|-------------------------------|-------------------------|
| Oral                        |                           |                               |                         |
| Chlorambucil                | Capecitabine              | Cyclophosphamide              | Hexamethylmelanine      |
| Erlotinib                   | Etoposide                 | Imatinib                      | Procarbazine            |
| Gefitinib                   | Everolimus                | Temozolamide                  |                         |
| Hydroxyurea                 | Fludarabine               | Vinorelbine                   |                         |
| Melphalan                   | Lapatinib                 | Treosulphan                   |                         |
| Methotrexate                | Lenalidomide              | Treosulphan                   |                         |
| Sorafenib                   | Sunitinib                 | Treosulphan                   |                         |
| 6-Thioguanine               | Thalidomide               | Treosulphan                   |                         |
| *Percentages indicate the risk of vomiting with intravenously administered antineoplastic agents in the absence of antiemetic prophylaxis; Data from Jordan et al. (2007), Roila et al. (2006, 2010).* |
Nausea and Vomiting

Antiemetic Prophylaxis Prevention of Acute Nausea and Vomiting

Before chemotherapy, it is crucial to clearly define the optimal prophylactic antiemetic therapy for acute and delayed nausea and vomiting and to implement it from the beginning, since symptom-oriented therapy at later stage is ineffective in most cases. This is important especially for the prophylaxis of delayed emesis. Emetogenic potential of the planned chemotherapy regimen needs to be established first. For patients who are taking chemotherapy on outpatients, it is important to decide treatment plan for the prophylaxis of delayed emesis.

Highly emetogenic chemotherapy

Patients should be treated with combination of 5-HT3-RA, a NK-1-RA (Aprepitant) and a corticosteroid.

Moderately emetogenic chemotherapy

Patients receiving AC chemotherapy for breast cancer should be treated with combination of 5-HT3-RA, a NK-1-RA (Aprepitant) and a corticosteroid. If Aprepitant is not available, women should receive a combination of Palanosetron plus dexamethasone (Roila et al., 2010).

Patients undergoing other moderately emetogenic chemotherapy should be given combination of with combination of 5-HT3-RA palanosetron and a corticosteroid dexamethasone.

Low emetogenic chemotherapy

Patients receiving low emetogenic chemotherapy should be treated with single agent such as low dose of corticosteroid. Patients of this group should not be overtreated with 5-HT3-RA routinely.

Minimally emetogenic chemotherapy

No antiemetic drug should be routinely administered before chemotherapy.

Prevention of Delayed Nausea and Vomiting

The presence of delayed emesis is often underestimated, with the consequence that no adequate preventive measures are taken.

Highly emetogenic chemotherapy

Routinely, Patients are treated with combination of NK-1-RA (Aprepitant) and a corticosteroid. The addition of 5-HT3-RA is not necessary most of the time (Schmoll et al., 2006).

Moderately emetogenic chemotherapy

Aprepitant or Fosaprepitant should be used to prevent delayed nausea and vomiting. A patient who has received Palanosetron for acute emesis, dexamethasone treatment is the preferred treatment for prevention of delayed nausea and vomiting. Patients can also be considered for multiday oral dexamethasone treatment for prevention of delayed emesis.

Low and minimally emetogenic chemotherapy

No prophylactic antiemetic treatment is planned for delayed emesis.

Therapy against Anticipatory Nausea and Vomiting (ANV)

ANV is a learned conditional reflex and drug therapy has modest efficacy. It may be best managed by psychological techniques, although this may not represent an easy solution in our day to day practice. The best approach is to avoid this by using optimal antiemetic prophylaxis from the first cycle. Conventional antiemetic are mostly ineffective however treatment with benzodiazepines in addition to conventional therapy has shown some efficacy if given before chemotherapy. Muscle relaxation, systemic desensitisation, hypnosis and cognitive distraction are possible interventions but its usefulness is doubtful.

Therapy in Cases of Insufficient Antiemetic Efficacy

If patient presents with emesis despite of preventive measures, it should first be checked that patient received the antiemetic according to guidelines. In general, a
### Table 2. Doses and Schedules of Antiemetic Agents with a High Therapeutic Index

| Drug | Dose | Before Chemotherapy (day 1) | After Chemotherapy |
|------|------|-----------------------------|-------------------|
| **High*** | | | |
| Dolasetron (Anzemet, Sanofi-Aventis) | Intravenous dose: 100 mg or 1.8mg/kg of body weight; oral dose: 100 mg | Oral dose: 100 mg on days 2 and 3 for MEC with potential for delayed emesis |
| Granisetron (Kytril, Roche) | Intravenous dose: 1 mg or 0.01 mg/kg; oral dose: 2 mg | Oral dose: 1 mg twice daily on days 2 and 3 for MEC with potential for delayed emesis |
| Ondansetron (Zofran, GlaxoSmithKline) | Intravenous dose: 8 mg or 0.15 mg/kg; oral dose: 24 mg for HEC, 8 mg twice daily for MEC | Oral dose: 8 mg twice daily on days 2 and 3 for MEC with potential for delayed emesis |
| Palonosetron (Aloxi, MGI Pharma) | Intravenous dose: 0.25 mg | Oral dose: 5 mg on days 2 and 3 for MEC with potential for delayed emesis |
| Tropisetron (Novoban, Novartis) | Intravenous dose: 5 mg; oral dose: 5 mg | Oral dose: 5 mg on days 2 and 3 for MEC with potential for delayed emesis |
| **Dexamethasone** | | | |
| With aprepitant or fosaprepitant | Intravenous dose: 12 mg; oral dose: 12 mg | Oral dose: 8 mg twice daily on days 2-4 for HEC, 8 mg on days 2 and 3 for MEC with potential for delayed emesis |
| Without aprepitant or Fosaprepitant | Intravenous dose: 20 mg for HEC, 8 mg for MEC; oral dose: 20 mg for HEC, 8 mg for MEC | Oral dose: 8 mg twice daily on days 2-4 for HEC, 8 mg on days 2 and 3 for MEC with potential for delayed emesis |
| Fosaprepitant (Emend [for injection], Merck) | Intravenous dose: 115 mg | Oral dose: 80 mg on days 2 and 3 |
| Aprepitant (Emend [capsules], Merck) | Oral dose: 125 mg | Oral dose: 80 mg on days 2 and 3 |
| **Low** | | | |
| Metoclopramide (Reglan, Baxter and Alaven) | Intravenous dose: 1-2 mg/kg of body weight* | Intravenous dose: 1-2 mg/kg 2 hr after chemotherapy; oral dose: 0.5 mg/kg every 6 hr on days 2-4 |
| Prochlorperazine (Compazine, GlaxoSmithKline) | Intravenous dose: 5-10 mg; oral dose: 5-10 mg | Oral dose: 5-10 mg every 6 hr as needed |
| Dronabinol (Marinol, Solvay) | Oral dose: 5 mg/m² of body-surface area | Oral dose: 5 mg/m² every 2-4 hr as needed |
| Nabilone (Cesamet, Valeant) | Oral dose: 1-2 mg | Oral dose: 1-2 mg twice daily or as needed |
| Olanzapine (Zyprexa, Eli Lilly) | Oral dose: 5 mg daily for 2 days preceding chemotherapy; 10 mg on day 1 | Oral dose: 10 mg on days 2-4 |

**This dose is for use only in patients who cannot tolerate or do not have a response to 5-HT3-receptor antagonists, dexamethasone, and aprepitant, given the risk of adverse neurologic events with this higher dose of metoclopramide.**

The prevention of chemotherapy-induced nausea and vomiting in cancer patients is critical. The use of antiemetic agents is essential to enhance patient comfort and to improve the quality of life. The table above provides a summary of the doses and schedules of antiemetic agents with a high therapeutic index. The selection of antiemetic agents should be based on the nature of the chemotherapy regimen and the patient's response to previous antiemetic treatment.

Moreover, the addition of palonosetron and dexamethasone to a 5-HT3-RA with a corticosteroid, and the use of aprepitant or Fosaprepitant for patients who received a combination of a 5-HT3-RA with a corticosteroid, and a NK-1-RA (Aprepitant/Fosaprepitant) should be considered.

With lasting emesis, the addition of metoclopramide, benzodiazepines, and neuroleptic agents and in particular olanzapine may be effective (Hesketh, 2008). The following drugs/doses can be used with caution in frequently sedated patients.

| Metoclopramide | 10 mg IV or 20-40mg PO every 4-6 hours |
| Olanzapine | 5-10 mg once |
| Benzodiazepine | Lorazepam: 1mg tablet one or two, Alprazolam: 0.25-1 mg tablet |
| Domperidone | 10-20 mg PO 3-4 times a day, Max.Daily dose 80 mg |
| Haloperidol | 0.5-2 mg PO 8-12 hourly, 1-2 mg short IV infusion |
| Promethazine | 25-50 mg PO 3-4 times a day |
| Chlorpromazine | 25-50 mg slow IV |
| Dronabinol | 5-10 mg PO every 3-6 hours, Max. daily dose 50 mg |
| PO: Per oral, IV: Intravenous |

In addition, other conditions like emetogenic drug therapy, brain metastasis and gastrointestinal obstructions leading to continuous emesis should be ruled out.
Therapy in Multiple Day chemotherapy

For multiple day cisplatin therapy, the use of a 5-HT3-R and a corticosteroid is recommended on the days when cisplatin is administered to the patients (Acute phase). In addition, for prophylaxis of delayed emesis, a corticosteroid alone should be administered. Aprepitant may be useful for multi-day chemotherapy regimens that are likely to be highly emetogenic. Use of 5-HT3-R an day 1-5 or Palanosetron on days 1, 3, 5 is also recommended (Roila et al., 2010).

Therapy in High Dose Chemotherapy

On the day when high-dose chemotherapy is administered (acute phase), the use of a 5-HT3-R and a corticosteroid is recommended before initiation of chemotherapy. On days 2-3 after high dose chemotherapy, a corticosteroid alone should be given for prevention of delayed nausea and vomiting. The addition of NK-1 RA or use of Palanosetron can be taken into consideration, although not recommended by recent guidelines.

Novel Therapy

Netupitant: Netupitant is a highly selective NK1 receptor antagonist, which is thought to work by blocking the action of substance P, an endogenous neurotransmitter contained in high concentrations in the vomiting center of the brainstem that can stimulate the vomiting reflex. Netupitant is currently under phase III trials.

Akynzeo: this is a fixed combination capsule of Netupitant and palonosetron, which is currently in Phase III trials helps in preventing CINV. The blockage of P/ NK1 receptors by Netupitant in the central nervous system inhibits the binding of endogenous tachykinin neuropeptide substance and this result in preventing the chemotherapy-induced nausea and vomiting. Moreover, Palonosetron helps in the blockage of serotonin at 5-hydroxytryptamine type 3 (5-HT3) receptors and it also helps in the chemotherapy-induced nausea and vomiting. USA FDA approved this drug on 10th October, 2014 for treatment of CINV.

References

Aapro MS, Molassiotis A, Oliver I (2005). Anticipatory nausea and vomiting. Support Care Cancer, 13, 117-21.
Aapro M, Rugo H, Rossi G et al. (2014). A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol, 25, 1328-33.
Bergstrom M, Hargreaves RJ, Burns HD, et al (2011). Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann N Y Acad Sci, 1222, 40-8.
Einhorn LH, Brames MJ, Dreicer R, et al (2007). Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer, 15, 1293-300.
Gralla RJ (1993). Current issues in the management of nausea and vomiting. Ann Oncol, 4, 3-7.
Gralla RJ, Bosnjak SM, Hontsa A, et al (2014). A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol, 25, 1333-9.
Gralla RJ, Osoba D, Kris MG, et al (1999). Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American society of clinical oncology. J Clin Oncol, 17, 2971.
Grunberg SM, Osoba D, Hesketh PJ, et al (2005). Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer, 13, 80-4.
Jordan K, Sippel C, Schmoll HJ (2007). Guidelines for antiemetic treatment of chemotherapy induced nausea and vomiting: past, present, and future recommendations. Oncologist, 12, 1143-50.
Hassan BA, Yusoff ZB (2010). Negative impact of chemotherapy on breast cancer patients QOL-utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev, 11, 1523-7.
Hesketh PJ (2008). Chemotherapy induced nausea and vomiting. N Engl J Med, 358, 2482-94.
Hesketh PJ, Gralla RJ, Bresnahan NA, et al (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomised, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the aprepitant protocol 052 study group. J Clin Oncol, 21, 4112-9.
Hesketh PJ, Kris MG, Gralla RJ, et al (1997). Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol, 15, 103-9.
Hesketh PJ, Rossi G, Rizzi G, et al (2014). Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized doseranging pivotal study. Ann Oncol, 25, 1340-6.
Jansins MC, Tejmani NA, Kamen C, et al (2013). Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother, 14, 757-66.
Keat CH, Ghani NA (2013). Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. Asian Pac J Cancer Prev, 14, 7701-6.
Koeller JM, Aapro MS, Gralla RJ, et al (2002). Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer, 10, 519-22.
Kris MG, Hesketh PJ, Somerfield MR, et al (2006). American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol, 24, 2932-47.
Musso M, Scalone R, Crescimanno A, et al (2010). Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant, 45, 123-7.
NCCN clinical Practice guidelines in oncology-antiemesis version 1, 2014, 2014). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive.
Rizzi A, Campi B, Camarda V, et al (2012). “In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist netupitant”. Peptides, 37, 86-97.
Roila F, Donati D, Tamberi S, Margutti G (2002). Delayed emesis: Incidence, pattern, prognostic factors and optimal
treatment. Support Care Cancer, 10, 88-95.
Roila F, Herrstedt J, Aapro M, et al (2010). Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 21, 232-43.
Roila F, Hesketh PJ, Herrstedt J (2006). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 perugia international antiemetic consensus conference. Ann Oncol, 17, 20-8.
Rojas C, Raje M, Tsukamoto T, Slusher BS (2014). Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol, 722, 26-37.
Rojas C, Thomas AG, Alt J, et al (2010). Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol, 626, 193-9.
Schmoll HJ, Aapro MS, Poli-Bigelli S, et al (2006). Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol, 17, 1000-6.
Wang SC, Borison HL (1950). The vomiting center; a critical experimental analysis. Arch Neurol Psychiatry, 63, 928-41.